Curemark adds two sites in California for CM-AT Phase III clinical trial program

Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that it has added two sites in California to its Phase III clinical trial program for CM-AT, the company's autism treatment.

The new sites are the University of California San Francisco (UCSF) and the Neuropsychiatric Research Center of Orange County (NRC) in Santa Ana.  Curemark opened CM-AT clinical trial enrollment at the UC Davis MIND Institute in Sacramento earlier this year.  The company now has 15 trial sites across the U.S. targeting to enroll a total 170 children in the study.  

"We now have trial sites participating in the autism study in major centers throughout California," said Dr. Joan Fallon, Curemark founder and CEO.  "There has been substantial interest in the CM-AT trials and we're continuing to expand the number of sites around the country."

CM-AT, which has received Fast Track status from the FDA, targets enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.  

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."